These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6150468)

  • 21. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats.
    Jelovac N; Sikiric P; Rucman R; Petek M; Marovic A; Perovic D; Seiwerth S; Mise S; Turkovic B; Dodig G; Miklic P; Buljat G; Prkacin I
    Eur J Pharmacol; 1999 Aug; 379(1):19-31. PubMed ID: 10499368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings.
    Chiu S; Paulose CS; Mishra RK
    Peptides; 1981; 2(1):105-11. PubMed ID: 6113579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitization versus tolerance to haloperidol-induced catalepsy: multiple determinants.
    Barnes DE; Robinson B; Csernansky JG; Bellows EP
    Pharmacol Biochem Behav; 1990 Aug; 36(4):883-7. PubMed ID: 2217518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New evidence that demonstrates that L-pro-L-leu-L-gly-NH2 might be the natural MIF.
    Vivas A; Celis ME
    Acta Physiol Lat Am; 1977; 27(4):177-82. PubMed ID: 31762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Tyr-W-MIF-1 analog containing D-Pro2 discriminates among antinociception in mice mediated by different classes of mu-opioid receptors.
    Nakayama D; Watanabe C; Watanabe H; Mizoguchi H; Sakurada T; Sakurada S
    Eur J Pharmacol; 2007 Jun; 563(1-3):109-16. PubMed ID: 17343845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tyr-MIF-1 and MIF-1 are active in the water wheel test for antidepressant drugs.
    Kastin AJ; Abel DA; Ehrensing RH; Coy DH; Graf MV
    Pharmacol Biochem Behav; 1984 Nov; 21(5):767-71. PubMed ID: 6151196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of prolyl-leucyl-glycinamide and alpha-melanocyte-stimulating hormone on levorphanol-induced analgesia, tolerance and dependence.
    Contreras PC; Takemori AE
    Life Sci; 1984 Jun; 34(26):2559-66. PubMed ID: 6146083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective effects of alpha-MSH and MIF-1 on the blood-brain barrier.
    Sankar R; Domer FR; Kastin AJ
    Peptides; 1981; 2(3):345-7. PubMed ID: 6117842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulatory effects of PLG and its peptidomimetics on haloperidol-induced catalepsy in rats.
    Costain WJ; Buckley AT; Evans MC; Mishra RK; Johnson RL
    Peptides; 1999; 20(6):761-7. PubMed ID: 10477133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cataleptogenic and anticataleptic activity produced by cholecystokinin octapeptides in mice.
    Kádár T; Borda L; Penke B; Kovács K; Telegdy G
    Neuropeptides; 1985 Jun; 6(3):259-68. PubMed ID: 4040614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrathecal Tyr-W-MIF-1 produces potent, naloxone-reversible analgesia modulated by alpha 2-adrenoceptors.
    Gergen KA; Zadina JE; Kastin AJ; Paul D
    Eur J Pharmacol; 1996 Mar; 298(3):235-9. PubMed ID: 8846821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of melanotrophin release inhibiting factor (MIF) and cyclo (Leu-Gly) on the tolerance to morphine-induced antinociception in the rat: a dose-response study.
    Bhargava HN
    Br J Pharmacol; 1981 Apr; 72(4):707-14. PubMed ID: 6116510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha-MSH and MIF-2 effects on serotonin levels and accumulation in various rat brain areas.
    Spirtes MA; Kostrzewa RM; Kastin AJ
    Pharmacol Biochem Behav; 1975; 3(6):1011-5. PubMed ID: 4814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of narcotic tolerance and physical dependence: effects of Pro-Leu-Gly-NH2 and cyclo (Leu-Gly).
    Bhargava HN; Walter R; Ritzmann RF
    Pharmacol Biochem Behav; 1980 Jan; 12(1):73-7. PubMed ID: 6102769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial 6-hydroxydopamine-induced lesions and haloperidol-induced catalepsy.
    Johnson SK; Fisher H; Wagner GC
    Neuropharmacology; 1993 Mar; 32(3):273-8. PubMed ID: 8474623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible aminergic mediation of MSH release and of the CNS effects of MSH and MIF-I.
    Kastin AJ; Schally AV; Kostrzewa RM
    Fed Proc; 1980 Sep; 39(11):2931-6. PubMed ID: 6105977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. alpha-MSH and Pro-Leu-Gly-NH2 (PLG; MIF-1): influence on dopamine (DA) uptake in crude synaptosomal preparations from rat mediobasal hypothalamus (MBH) and caudate putamen (CP).
    Torre E; Celis ME; Chiocchio SR
    Peptides; 1984; 5(4):669-74. PubMed ID: 6149522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of melanotropin release inhibiting factor on changes by haloperidol and centbutindole in cerebral cortical 5-hydroxytryptamine receptors.
    Gulati A; Bhargava HN
    Pharmacology; 1990; 41(2):98-106. PubMed ID: 1979878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of prolyl-leucyl-glycinamide and cyclo(leucyl-glycine) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to rats.
    Bhargava HN
    Neuropharmacology; 1984 Apr; 23(4):439-44. PubMed ID: 6145116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosing time-dependent tolerance of catalepsy by repetitive administration of haloperidol in mice.
    Viyoch J; Ohdo S; Yukawa E; Higuchi S
    J Pharmacol Exp Ther; 2001 Sep; 298(3):964-9. PubMed ID: 11504791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.